{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:39:19Z","timestamp":1793126359499,"version":"4.5.0"},"reference-count":132,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Transformative therapeutic innovation should not begin with a molecule\u2014or even a molecular target. It should begin with a clearly defined unmet clinical need. Here, we present a seven-step Translational Therapeutic Development Roadmap that systematically connects an unmet medical need to a developable drug candidate through the disciplined sequence of (i) defining the need, (ii) understanding disease and resistance biology, (iii) building a mechanistic hypothesis, (iv) defining a target product profile (TPP), (v) molecular design and experimental validation, (vi) developability and manufacturability assessment, and (vii) clinical translation. A central conclusion emerging from this review is that resistance biology should be viewed not merely as a cause of therapeutic failure, but as a primary design input for next-generation therapeutic innovation. Our analysis identifies continuous alignment among unmet clinical needs, resistance biology, mechanistic hypothesis, molecular design, developability, and clinical translation as the defining characteristic of successful therapeutic development. We use dual-payload antibody\u2013drug conjugates (ADCs) as a contemporary and highly illustrative case study of this resistance-informed therapeutic development approach. Single-payload ADCs such as trastuzumab deruxtecan and sacituzumab govitecan have transformed treatment across multiple solid tumors, yet most patients ultimately relapse through antigen loss, defective intracellular trafficking, drug efflux, payload-target alterations, and tumor heterogeneity, creating an emerging post-ADC treatment gap. Dual-payload ADCs, which deliver two mechanistically distinct warheads from a single antibody, represent a form of molecular combination therapy designed to increase the barrier to resistance and address multiple escape pathways simultaneously, as well as provide a clinically relevant model for resistance-informed therapeutic design. Using dual-payload ADCs as a worked example, we demonstrate how resistance biology directly informs payload pairing, molecular architecture, conjugation strategy, experimental validation, and developability. Our analysis indicates that successful dual-payload ADC design depends not simply on combining two cytotoxic payloads, but on selecting complementary mechanisms with non-overlapping resistance liabilities while satisfying predefined target product profiles and manufacturability requirements. We further summarize resistance-guided payload pairing strategies, including topoisomerase I plus tubulin inhibitors, topoisomerase I plus DNA-damage-response inhibitors, cytotoxic plus immunomodulatory payloads, and cell-permeable plus non-permeable combinations; the conjugation chemistries that enable defined dual-payload products; the preclinical validation, pharmacological optimization, and developability hurdles that separate promising biology from viable therapeutics; and the rapidly expanding clinical landscape, including the first-in-human program KH815 and emerging bispecific dual-payload constructs. Finally, we demonstrate that the same translational roadmap extends beyond ADCs to radiopharmaceutical conjugates, multispecific antibodies, targeted protein degraders, and cell and gene therapies, indicating that it represents a general framework for therapeutic innovation rather than an ADC-specific strategy. Collectively, this review supports the concept that therapeutic innovation is most successful when unmet clinical needs, resistance biology, molecular design, developability, and clinical translation are considered as an integrated continuum rather than as independent stages of drug discovery. This Translational Therapeutic Development Roadmap provides an organizing framework for guiding the rational development of next-generation targeted therapeutics across diverse therapeutic modalities.<\/jats:p>","DOI":"10.3390\/biom16071052","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:47:32Z","timestamp":1784508452000},"page":"1052","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["From Unmet Medical Need to Drug Candidate: A Translational Therapeutic Development Roadmap Illustrated by Dual-Payload Antibody\u2013Drug Conjugates"],"prefix":"10.3390","volume":"16","author":[{"given":"Takeshi","family":"Honda","sequence":"first","affiliation":[{"name":"SparX Biopharmaceutical Corp., 700 E Business Center Dr, Mount Prospect, IL 60056, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Dong","family":"Zhu","sequence":"additional","affiliation":[{"name":"SparX Biopharmaceutical Corp., 700 E Business Center Dr, Mount Prospect, IL 60056, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e70416","DOI":"10.1002\/cncr.70416","article-title":"Integrating Antibody\u2013Drug Conjugates into Solid Tumor Oncology: Current Standards and Future Directions","volume":"132","author":"Mansinho","year":"2026","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A History of Cancer Chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted Cancer Therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Chemotherapy and the War on Cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013Drug Conjugates in Cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the Potential of Antibody\u2013Drug Conjugates for Cancer Therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013Drug Conjugates Come of Age in Oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and Challenges for the Next Generation of Antibody\u2013Drug Conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0192623318803059","article-title":"A Brief Introduction to Antibody\u2013Drug Conjugates for Toxicologic Pathologists","volume":"46","author":"Mecklenburg","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody\u2013Drug Conjugates: An Emerging Concept in Cancer Therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of Potent Monoclonal Antibody Auristatin Conjugates for Cancer Therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential Drugs Used in the Antibody\u2013Drug Conjugate (ADC) Architecture for Cancer Therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I Inhibitors: Camptothecins and Beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload Diversification: A Key Step in the Development of Antibody\u2013Drug Conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer Drug Resistance: An Evolving Paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A View on Drug Resistance in Cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal Evolution in Cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_29","first-page":"18","article-title":"Antibody\u2013Drug Conjugates in Breast Cancer Treatment: Resistance Mechanisms and the Role of Therapeutic Sequencing","volume":"8","author":"Valle","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody\u2013Drug Conjugates with Dual Payloads for Combating Breast Tumor Heterogeneity and Drug Resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous Antibody\u2013Drug Conjugates with Dual Payloads: Potential, Methods and Considerations","volume":"17","author":"Wen","year":"2025","journal-title":"mAbs"},{"key":"ref_32","unstructured":"U.S. Food and Drug Administration (2007). Guidance for Industry and Review Staff: Target Product Profile\u2014A Strategic Development Process Tool, FDA."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody\u2013Drug Conjugates: Lessons Learned and Future Directions","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-025-00868-y","article-title":"Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multi-Omic Molecular Profiling","volume":"12","author":"Sledge","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding","volume":"16","author":"Chen","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Corti, C., Giugliano, F., Nicol\u00f2, E., Tarantino, P., and Curigliano, G. (2021). Antibody\u2013Drug Conjugates for the Treatment of Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13122898"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-Positive Breast Cancer: Advances and Future Directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1078-0432.CCR-18-1976","article-title":"HER2-Overexpressing Cancers: Mechanistic Insights into Trastuzumab and Future Therapies","volume":"26","author":"Pegram","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1538-7445.AM2025-558","article-title":"MUC1*-Deruxtecan Kills Tumors That Have Acquired Resistance to Trastuzumab-Containing Therapeutics","volume":"85","author":"Bamdad","year":"2025","journal-title":"Cancer Res."},{"key":"ref_44","first-page":"165","article-title":"Antibody\u2013Drug Conjugates: Smart Chemotherapy Delivery Across Tumor Histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to Antibody\u2013Drug Conjugates","volume":"78","author":"Pandiella","year":"2018","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of Resistance to Antibody\u2013Drug Conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., and Lecesne, A. (2023). Mechanisms of Resistance to Antibody\u2013Drug Conjugates. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119674"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the Antibody\u2013Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity","volume":"77","author":"Arribas","year":"2017","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","article-title":"SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm","volume":"75","author":"Hamblett","year":"2015","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a Potential Predictive Biomarker for Antibody\u2013Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21141","DOI":"10.18632\/oncotarget.24975","article-title":"Esophageal Cancer Cells Resistant to T-DM1 Display Alterations in Cell Adhesion and the Prostaglandin Pathway","volume":"9","author":"Sauveur","year":"2018","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","article-title":"The DNA Repair Pathway as a Therapeutic Target to Synergize with Trastuzumab Deruxtecan in HER2-Targeted ADC-Resistant HER2-Overexpressing Breast Cancer","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wang, D.K., Steele, J.A., Opalenik, S.R., and Balko, J.M. (2026). Topoisomerase I Inhibitor Antibody\u2013Drug Conjugates in Breast Cancer: The Relevance of the DNA Damage Response to Resistance, Response, and Combination Treatment Strategies. Breast Cancer Res. Treat.","DOI":"10.1007\/s10549-026-07964-y"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody Drug Conjugates and Bystander Killing: Is Antigen-Dependent Internalisation Required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Collins, D.M., Bossenmaier, B., Kollmorgen, G., and Niederfellner, G. (2019). Acquired Resistance to Antibody\u2013Drug Conjugates. Cancers, 11.","DOI":"10.3390\/cancers11030394"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming Resistance to Antibody\u2013Drug Conjugates: From Mechanistic Insights to Cutting-Edge Strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"oyag020","DOI":"10.1093\/oncolo\/oyag020","article-title":"Mechanisms and Emerging Strategies to Overcome Resistance to Antibody\u2013Drug Conjugates","volume":"31","author":"Inase","year":"2026","journal-title":"The Oncologist"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Xie, D., Yang, C., Gao, S., Li, J., Yang, J., Li, X., Jiang, R., Cao, F., Zhang, S., and Wang, L. (2026). Antibody\u2013Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27073287"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander Killing Effect of DS-8201a, a Novel Anti-HER2 Antibody\u2013Drug Conjugate, in Tumors with HER2 Heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP Inhibitors: Synthetic Lethality in the Clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/anie.201608292","article-title":"Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody\u2013Drug Conjugates","volume":"56","author":"Levengood","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_66","first-page":"71","article-title":"Dual-Mechanistic Antibody\u2013Drug Conjugate via Site-Specific Selenocysteine\/Cysteine Conjugation","volume":"2","author":"Nilchan","year":"2019","journal-title":"Antib. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"110839","DOI":"10.1016\/j.celrep.2022.110839","article-title":"Homogeneity of Antibody\u2013Drug Conjugates Critically Impacts the Therapeutic Efficacy in Brain Tumors","volume":"39","author":"Anami","year":"2022","journal-title":"Cell Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/1878-0261.70198","article-title":"Combining Antibody Conjugates with Cytotoxic and Immune-Stimulating Payloads Maximizes Anti-Cancer Activity","volume":"20","author":"Wang","year":"2026","journal-title":"Mol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","article-title":"A Dual-Payload Antibody\u2013Drug Conjugate Targeting CD276\/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer","volume":"84","author":"Zhou","year":"2024","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding Pharmaceutical Quality by Design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nbt.3274","article-title":"Site-Specific Conjugation Improves Therapeutic Index of Antibody\u2013Drug Conjugates with High Drug Loading","volume":"33","author":"Strop","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","article-title":"Analytical Methods for Physicochemical Characterization of Antibody\u2013Drug Conjugates","volume":"3","author":"Wakankar","year":"2011","journal-title":"mAbs"},{"key":"ref_73","unstructured":"Biointron (2025). The Rise of Multi-Payload ADCs in Oncology, Biointron. Biointron Antibody Industry Trends."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1021\/acs.bioconjchem.5c00239","article-title":"SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations","volume":"36","author":"Sun","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","article-title":"New Life of Topoisomerase I Inhibitors as Antibody\u2013Drug Conjugate Warheads","volume":"29","author":"Pommier","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1158\/1538-7445.AM2025-1804","article-title":"An innovative dual-payload ADC combining topoisomerase 1 inhibitor and a tubulin inhibitor efficiently overcomes drug resistance Free","volume":"85","author":"Shan","year":"2025","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013Drug Conjugates: Recent Advances in Payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Goldenberg, D.M., and Sharkey, R.M. (2022). The Potential of Topoisomerase Inhibitor-Based Antibody\u2013Drug Conjugates. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081707"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1038\/s41467-025-64509-5","article-title":"Tumor-Targeted Top1 Inhibitor Delivery with Optimized PARP Inhibition in Advanced Solid Tumors: A Phase I Trial of Gapped Scheduling","volume":"16","author":"Thomas","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-Stimulating Antibody Conjugates Elicit Robust Myeloid Activation and Durable Antitumor Immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bhatnagar, S., Revuri, V., Shah, M., Larson, P., Shao, Z., Yu, D., Prabha, S., Griffith, T.S., Ferguson, D., and Panyam, J. (2022). Combination of STING and TLR7\/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy. Cancers, 14.","DOI":"10.3390\/cancers14246091"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.jmedchem.2c01791","article-title":"Degrader\u2013Antibody Conjugates: Emerging New Modality","volume":"66","author":"Hong","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.7150\/thno.102531","article-title":"A Novel ROR1-Targeting Antibody\u2013PROTAC Conjugate Promotes BRD4 Degradation for Solid Tumor Treatment","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC Targeted Protein Degraders: The Past Is Prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical Therapy in Cancer: Clinical Advances and Challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"16101","DOI":"10.1073\/pnas.1211023109","article-title":"Synthesis of Site-Specific Antibody\u2013Drug Conjugates Using Unnatural Amino Acids","volume":"109","author":"Axup","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/bc400490z","article-title":"Production of Site-Specific Antibody\u2013Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System","volume":"25","author":"Zimmerman","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody\u2013Drug Conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.biotechadv.2015.05.001","article-title":"Current Methods for the Synthesis of Homogeneous Antibody\u2013Drug Conjugates","volume":"33","author":"Sochaj","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Gulyak, E.L., Komarova, O.A., Prokopenko, Y.A., Faizullina, E.A., Malabuiok, D.M., Ibragimova, A.R., Mokrushina, Y.A., Serova, O.V., Popova, G.P., and Zhitlov, M.Y. (2024). Branched Linkers for Homogeneous Antibody\u2013Drug Conjugates: How Long Is Long Enough?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413356"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"108841","DOI":"10.1016\/j.biotechadv.2026.108841","article-title":"Multivalent Linkers: A Growing Trend in Antibody\u2013Drug Conjugate Development","volume":"89","author":"Gulyak","year":"2026","journal-title":"Biotechnol. Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1538-7445.AM2025-1586","article-title":"KH815, a Novel Dual-Payload TROP2-Directed Antibody\u2013Drug Conjugate, Shows Potent Antitumor Efficacy in Preclinical Tumor Models","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Res."},{"key":"ref_94","unstructured":"Plieth, J. (2026, July 06). The First Clinical-Stage Dual-Payload Conjugate. Available online: https:\/\/www.apexonco.com\/first-clinical-stage-dual-payload-conjugate."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1021\/bc5004982","article-title":"Site-Specific Antibody\u2013Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development","volume":"26","author":"Agarwal","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Wilski, N.A., Haytko, P., Zha, Z., Wu, S., Jin, Y., Chen, P., Han, C., and Chiu, M.L. (2025). A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17080967"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1158\/1538-7445.AM2025-5451","article-title":"An innovative site-specific dual-payload bispecific antibody drug conjugate targeting EGFR and HER3 exhibits potent preclinical activities","volume":"85","author":"Xu","year":"2025","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific Antibody Drug Conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-Derived Organoids Model Treatment Response of Metastatic Gastrointestinal Cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody\u2013Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10928-012-9276-y","article-title":"Bench to Bedside Translation of Antibody Drug Conjugates Using a Multiscale Mechanistic PK\/PD Model","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1208\/s12248-015-9790-0","article-title":"Antibody\u2013Drug Conjugates: Nonclinical Safety Considerations","volume":"17","author":"Hinrichs","year":"2015","journal-title":"AAPS J."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Abelman, R.O., Wu, B., Spring, L.M., Ellisen, L.W., and Bardia, A. (2023). Mechanisms of Resistance to Antibody\u2013Drug Conjugates. Cancers, 15.","DOI":"10.3390\/cancers15041278"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/19420862.2017.1412025","article-title":"Challenges and New Frontiers in Analytical Characterization of Antibody\u2013Drug Conjugates","volume":"10","author":"Wagh","year":"2018","journal-title":"mAbs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/elps.202200140","article-title":"Switching Positions: Assessing the Dynamics of Conjugational Heterogeneity in Antibody\u2013Drug Conjugates Using CE-SDS","volume":"44","author":"Hendriks","year":"2023","journal-title":"Electrophoresis"},{"key":"ref_107","first-page":"23","article-title":"The Process Is the Product: Navigating CMC Complexities in ADC Development","volume":"9","author":"White","year":"2025","journal-title":"Prem. Res. Perspect."},{"key":"ref_108","unstructured":"ICH (1999). Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products, International Council for Harmonisation."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA Oncology Analysis of Antibody\u2013Drug Conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Metrangolo, V., and Engelholm, L.H. (2024). Antibody\u2013Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. Cancers, 16.","DOI":"10.3390\/cancers16020447"},{"key":"ref_111","unstructured":"Plieth, J. (2026, July 06). AACR 2025 Preview\u2014A Surge in Dual-Payload Conjugates. ApexOnco (Oncology Pipeline), Available online: https:\/\/www.apexonco.com\/aacr-2025-preview-surge-dual-payload-conjugates."},{"key":"ref_112","unstructured":"BioPharma APAC (2026, July 06). Driving Oncology Forward: 25 Companies Redefining Antibody\u2013Drug Conjugates in 2025. Available online: https:\/\/biopharmaapac.com\/news\/25\/5703\/driving-oncology-forward-25-companies-redefining-antibody-drug-conjugates-adcs-in-2025.html."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Long, R., Zuo, H., Tang, G., Zhang, C., Yue, X., Yang, J., Luo, X., Deng, Y., Qiu, J., and Li, J. (2025). Antibody\u2013Drug Conjugates in Cancer Therapy: Applications and Future Advances. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1516419"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41698-025-01159-2","article-title":"Leveraging Artificial Intelligence in Antibody\u2013Drug Conjugate Development: From Target Identification to Clinical Translation in Oncology","volume":"9","author":"Lu","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_115","unstructured":"Fierce Biotech (2026, July 06). Beyond the ADC Hype: Innovation Accelerating Through Bispecifics and Dual-Payload Strategies. Available online: https:\/\/www.fiercebiotech.com\/sponsored\/beyond-adc-hype-innovation-accelerating-through-bispecifics-and-dual-payload-strategies."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Jang, H., and Chang, J.-E. (2025). Strategic Combinations of Antibody\u2013Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens. Pharmaceuticals, 17.","DOI":"10.3390\/pharmaceutics17121581"},{"key":"ref_117","unstructured":"Immunome, Inc. (2025). IM-1021 (ROR1) and HC74 Payload Platform, Immunome, Inc.. Form 8-K."},{"key":"ref_118","unstructured":"Sutro Biopharma (2025). Pipeline Update and Selection of STRO-004 as Lead Clinical Candidate; Form 8-K, Sutro Biopharma Inc."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of ^177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Lesperance, J., Yung, B.S., Allevato, M.M., Cheng, M.M., Camargo, M.F., Saddawi-Konefka, R., Dhawan, K., Sharma, A.K., Mortaja, M., and Bice, S. (2025). Interactions of Antibody\u2013Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy. Adv. Sci., e06552.","DOI":"10.1002\/advs.202506552"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"119259","DOI":"10.1016\/j.biopha.2026.119259","article-title":"Immune Checkpoint Targeted Drug Conjugate Therapies: Bridging Preclinical and Clinical Innovation for Solid Tumor Therapy","volume":"198","author":"Almalki","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-Extra Domain B Splice Variant of Fibronectin Antibody\u2013Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.addr.2011.12.010","article-title":"Cancer Stromal Targeting (CAST) Therapy","volume":"64","author":"Matsumura","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-Internalizing Antibody\u2013Drug Conjugates Display Potent Anti-Cancer Activity upon Proteolytic Release of Monomethyl Auristatin E in the Subendothelial Extracellular Matrix","volume":"140","author":"Stringhini","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1172\/JCI120481","article-title":"Tumor Stroma-Targeted Antibody\u2013Drug Conjugate Triggers Localized Anticancer Drug Release","volume":"128","author":"Szot","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific Antibodies: A Mechanistic Review of the Pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-024-02062-1","article-title":"TransTACs: Novel Heterobispecific Antibodies for Targeted Protein Degradation in Cancer Therapy","volume":"9","author":"Walther","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_129","unstructured":"Orum Therapeutics (2026, July 06). ORM-6151 Degrader\u2013Antibody Conjugate (Anti-CD33\/GSPT1) and Pipeline Update. Press Release. Available online: https:\/\/www.orumrx.com\/news."},{"key":"ref_130","unstructured":"(2026, July 06). When ADCs Meet Targeted Protein Degraders: The Emerging Field of Degrader\u2013Antibody Conjugates. Available online: https:\/\/www.labiotech.eu\/in-depth\/degrader-antibody-conjugates-review\/."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T Cell Immunotherapy for Human Cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene Therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/7\/1052\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:52:27Z","timestamp":1784623947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/7\/1052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":132,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["biom16071052"],"URL":"https:\/\/doi.org\/10.3390\/biom16071052","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]}}}